The United Therapeutics Corporation will hold its Q4 2024 Earnings Conference Call on February 26, 2025, at 9:00 AM ET. Key company participants include Martine Rothblatt, the Chairperson and CEO, along with other executives. The call will be hosted by Cindy, the conference operator, who will welcome everyone to the update.
United Therapeutics (UTHR) reported quarterly earnings of $6.19 per share, which is higher than the Zacks Consensus Estimate of $6.10 per share. This is an increase compared to earnings of $4.36 per share from the same period last year.
UTHR exceeded expectations for both earnings and sales in the fourth quarter. However, Tyvaso sales did not meet the projected figures.
United Therapeutics is considered to be undervalued, with a price-to-earnings ratio of 16x and an EV/EBITDA of 8.64x, while the sector averages are 28x and 15.15x. The company is experiencing significant revenue growth, particularly from Tyvaso, which has increased by 33% year-over-year, and it has strong profit margins and low debt. Major factors for future growth include Tyvaso's entry into the IPF market, advancements in Ralinepag, breakthroughs in xenotransplantation, and expansion into international markets.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
Investors looking at stocks in the Medical - Drugs sector may be familiar with United Therapeutics (UTHR) and Stevanato Group (STVN). However, which of these two stocks is more appealing for value investors?
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.
UTHR has strong advantages, such as high capital returns and effective profit reinvestment, which create a positive outlook. In the third quarter of fiscal year 2024, United Therapeutics reported impressive growth in its main products, with Tyvaso, Orenitram, and Unituxin all showing significant year-on-year increases. I estimate that the company's earnings could grow by 40% in the next 2-3 years.
United Therapeutics is a top company in treating pulmonary arterial hypertension (PAH), mainly due to its main product, Tyvaso, which generates most of its income. The company is also making advancements in organ transplants and bioengineered organs, such as xenotransplantation and ex vivo lung perfusion, which could change the industry. However, ongoing legal disputes, especially with Liquidia, pose risks to United Therapeutics' intellectual property and could impact its position in the PAH market.